These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30595885)

  • 1. Correlation between Immunohistochemical Subtype and Clinicopathological Features in Patients with Diffuse Large B-cell Lymphoma.
    Patrascu AM; Streba L; Patrascu Ş; Nacea J; Mogoanta L; Rotaru I
    Curr Health Sci J; 2017; 43(3):253-257. PubMed ID: 30595885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm.
    Montalbán C; Díaz-López A; Martín A; Baile M; Sanchez JM; Sancho JM; García O; Novelli S; Monter-Rovira A; Salar A; Bastos M; Gutiérrez A; Bento L; Córdoba R; Arquero T; González de Villambrosia S; Barranco G; De Oña R; López Guillermo A; Rodriguez Salazar MJ; Domínguez JF; Fernández R; Queizan JA; Rodríguez J; Abraira V; García JF;
    Br J Haematol; 2018 Aug; 182(4):534-541. PubMed ID: 29978453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of total lesion glycolysis and cell-of-origin subtypes for prognostic stratification of diffuse large B-cell lymphoma patients.
    Jiang C; Teng Y; Zheng Z; Zhou Z; Xu J
    Quant Imaging Med Surg; 2021 Jun; 11(6):2509-2520. PubMed ID: 34079720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
    Huang H; Fan L; Fu D; Lin Q; Shen J
    Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of diffuse large B-cell lymphoma of germinal center B-cell origin in whole diffuse large B-cell lymphoma: tissue fluorescence in situ hybridization using t(14;18) compared with immunohistochemistry.
    Hirose Y; Masaki Y; Karasawa H; Shimoyama K; Fukushima T; Kawabata H; Ogawa N; Wano Y; Ozaki M
    Int J Hematol; 2005 Jan; 81(1):48-57. PubMed ID: 15717689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunohistochemical classification and prognosis of diffuse large B-cell lymphoma in China].
    Chen Y; Xiao L; Zhu X; Lu C; Yu B; Fan D; Yin Y
    Zhonghua Bing Li Xue Za Zhi; 2014 Jun; 43(6):383-8. PubMed ID: 25208988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
    Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
    Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Cell-Origin Profiling Using Immunohistochemistry to Predict the Survival of Patients with Diffuse Large B-Cell Lymphoma in Indonesia.
    Istiadi H; Sadhana U; Puspasari D; Miranti IP; Karlowee V; Listiana DE; Prasetyo A
    Yonago Acta Med; 2021 May; 64(2):200-206. PubMed ID: 34025195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The clinical characteristics of 681 patients with diffuse large B-cell lymphoma].
    Wen JJ; Liu ZB; Xu J; Xu CG
    Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1004-9. PubMed ID: 23363791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ki67 Proliferation Index in Germinal and Non-Germinal Subtypes of Diffuse Large B-Cell Lymphoma.
    Hashmi AA; Iftikhar SN; Nargus G; Ahmed O; Asghar IA; Shirazi UA; Afzal A; Irfan M; Ali J
    Cureus; 2021 Feb; 13(2):e13120. PubMed ID: 33728138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-germinal center B-cell subtype of pediatric diffuse large B-cell lymphoma in Japan: A retrospective cohort study.
    Hori D; Kobayashi R; Nakazawa A; Iwafuchi H; Klapper W; Osumi T; Ohk K; Sekimizu M
    Pediatr Blood Cancer; 2023 May; 70(5):e30279. PubMed ID: 36860130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival.
    Haarer CF; Roberts RA; Frutiger YM; Grogan TM; Rimsza LM
    Arch Pathol Lab Med; 2006 Dec; 130(12):1819-24. PubMed ID: 17149956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma.
    Chuang WY; Chang H; Shih LY; Wang PN; Chang YS; Lin TL; Hung YS; Yeh CJ; Ueng SH; Tang TC; Kuo MC; Dunn P; Wu JH; Kao HW; Ou CW; Wan YL; Hsueh C
    Virchows Arch; 2015 Nov; 467(5):571-82. PubMed ID: 26369546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical subtyping of diffuse large B-cell lymphoma into germinal center B-cell and activated B-cell subtype, along with correlation of the subtypes with extranodal involvement, serum lactate dehydrogenase, and positron emission tomography scan-based response assessment to chemotherapy.
    Tyagi A; Abrari A; Khurana A; Tyagi S
    J Cancer Res Ther; 2022; 18(4):1129-1136. PubMed ID: 36149172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blimp-1 protein and Hans classification on prognosis of diffuse large B-cell lymphoma and their interrelation.
    Song Y; Cao Z; Li L; Zhang HT; Zhang X
    Chin J Cancer; 2010 Sep; 29(9):781-6. PubMed ID: 20800019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of prognostic factors in diffuse large B-cell lymphoma associated with rheumatic diseases.
    Gorodetskiy V; Probatova N; Obukhova T; Vasilyev V
    Lupus Sci Med; 2021 Nov; 8(1):. PubMed ID: 34785569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma.
    Tang H; Zhou H; Wei J; Liu H; Qian W; Chen X
    Hematology; 2019 Dec; 24(1):446-454. PubMed ID: 31072235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Cho MC; Chung Y; Jang S; Park CJ; Chi HS; Huh J; Suh C; Shim H
    Medicine (Baltimore); 2018 Nov; 97(45):e13046. PubMed ID: 30407302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.